Supplementary Figure S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial

Supplementary Figure S2 | Dose de-escalation design and criteria to dose expansion. aIf ≥2 DLT occur in the first six patients, a decision had to be made on whether to expand DL1 to 10 additional patients or to de-escalate ipatasertib dose to DL-1. DL, dose level; DLT, dose-limiting toxicity.